March 2024
1. ZHENG W, Peng W, Qian F, Zhang M, et al
   Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-kappaB signaling and reducing NLRP3 expression in triple-negative breast cancer.
   Cancer Chemother Pharmacol. 2024 Mar 8. doi: 10.1007/s00280-024-04660.
   

   >> Share

   
   
2. YUCEL KB, Aydos U, Sutcuoglu O, Kilic ACK, et al
   Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
   Cancer Chemother Pharmacol. 2024 Mar 4. doi: 10.1007/s00280-024-04641.
   

   >> Share

   
   
3. MITTRA A, Coyne GHOS, Zlott J, Kummar S, et al
   Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
   Cancer Chemother Pharmacol. 2024;93:177-189.
   

   >> Share

   
   February 2024
4. ELKASAR AO, Hussien FZ, Abdel-Hamied HE, Saleh IG, et al
   Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
   Cancer Chemother Pharmacol. 2024 Feb 7. doi: 10.1007/s00280-023-04620.
   

   >> Share

   
   December 2023
5. XU S, Shi Y, Li S
   Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/beta-catenin signaling pathway in breast cancer.
   Cancer Chemother Pharmacol. 2023 Dec 5. doi: 10.1007/s00280-023-04618.
   

   >> Share

   
   September 2023
6. JABLONSKI M, Rodriguez MS, Rivero EM, Bruque CD, et al
   The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
   Cancer Chemother Pharmacol. 2023 Sep 19. doi: 10.1007/s00280-023-04586.
   

   >> Share

   
   August 2023
7. BEUMER JH, Foldi J
   Pharmacology and pharmacokinetics of elacestrant.
   Cancer Chemother Pharmacol. 2023;92:157-163.
   

   >> Share

   
   June 2023
8. XU G, Yang D, He C, Zhong L, et al
   Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer.
   Cancer Chemother Pharmacol. 2023 Jun 28. doi: 10.1007/s00280-023-04559.
   

   >> Share

   
   May 2023
9. VARNIER R, Puszkiel A, Tod M, Calattini S, et al
   Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
   Cancer Chemother Pharmacol. 2023;91:361-373.
   

   >> Share

   
   March 2023
10. EL-SADONI M, Shboul SA, Alhesa A, Shahin NA, et al
    A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2023 Mar 24. doi: 10.1007/s00280-023-04523.
    

    >> Share

    
    February 2023
11. LI C, Hao M, Fang Z, Ding J, et al
    PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials.
    Cancer Chemother Pharmacol. 2023 Feb 2. doi: 10.1007/s00280-023-04506.
    

    >> Share

    
    January 2023
12. HJORTH CF, Damkier P, Stage TB, Feddersen S, et al
    The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
    Cancer Chemother Pharmacol. 2023 Jan 4. doi: 10.1007/s00280-022-04499.
    

    >> Share

    
    November 2022
13. XIAO H, Yang X, Huang S
    SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration.
    Cancer Chemother Pharmacol. 2022 Nov 27. doi: 10.1007/s00280-022-04496.
    

    >> Share

    
    
14. TABUCHI Y, Tsujimoto M, Yamamoto K, Kosaka T, et al
    Incidence and risk factors of infusion reactions in patients with breast cancer administered trastuzumab plus pertuzumab-based regimen.
    Cancer Chemother Pharmacol. 2022 Nov 19. doi: 10.1007/s00280-022-04492.
    

    >> Share

    
    
15. PROCTOR JR, Gartner EM, Gray TE, Davies RH, et al
    Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
    Cancer Chemother Pharmacol. 2022;90:399-408.
    

    >> Share

    
    October 2022
16. JIAN W, Xue J, Yao Q, Chen R, et al
    Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic-pharmacodynamic model of neutropenia.
    Cancer Chemother Pharmacol. 2022 Oct 22. pii: 10.1007/s00280-022-04484.
    

    >> Share

    
    
17. SHARAF BM, Giddey AD, Al-Hroub HM, Menon V, et al
    Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab.
    Cancer Chemother Pharmacol. 2022 Oct 20. pii: 10.1007/s00280-022-04478.
    

    >> Share

    
    April 2022
18. MANZO J, Puhalla S, Pahuja S, Ding F, et al
    A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2022 Apr 18. pii: 10.1007/s00280-022-04430.
    

    >> Share

    
    February 2022
19. LIANG Z, Feng A, Shim H
    Retraction Note to: MicroRNA30cregulated HDAC9 mediates chemoresistance of breast cancer.
    Cancer Chemother Pharmacol. 2022 Feb 24. pii: 10.1007/s00280-022-04409.
    

    >> Share

    
    
20. NICOLETTO RE, Ofner CM 3rd
    Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.
    Cancer Chemother Pharmacol. 2022 Feb 12. pii: 10.1007/s00280-022-04400.
    

    >> Share

    
    
21. HUANG Y, Yang S, Yu W, Gui L, et al
    Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil.
    Cancer Chemother Pharmacol. 2022 Feb 8. pii: 10.1007/s00280-021-04391.
    

    >> Share

    
    
22. REDA M, Macaire P, Bellio H, Uwer L, et al
    Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
    Cancer Chemother Pharmacol. 2022;89:197-208.
    

    >> Share

    
    January 2022
23. TAN AR, Chan N, Kiesel BF, Stein MN, et al
    A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
    Cancer Chemother Pharmacol. 2022;89:49-58.
    

    >> Share

    
    October 2021
24. YAO HM, Jones SR, Morales S, Moosavi S, et al
    Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
    Cancer Chemother Pharmacol. 2021 Oct 7. pii: 10.1007/s00280-021-04355.
    

    >> Share

    
    
25. ROY P, Biswas S, Acharyya S, Dasgupta C, et al
    Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study.
    Cancer Chemother Pharmacol. 2021;88:731-740.
    

    >> Share

    
    
26. LEENHARDT F, Alexandre M, Guiu S, Pouderoux S, et al
    Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy.
    Cancer Chemother Pharmacol. 2021;88:723-729.
    

    >> Share

    
    September 2021
27. CHEN L, Chen CS, Sun Y, Henry NL, et al
    Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
    Cancer Chemother Pharmacol. 2021;88:475-483.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share